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to the LAC arm who were converted to open colectomy were
included in the LAC group in the analysis. RESULTS: Among
855 patients, length of stay (mean: 5.5 vs. 6.7 days) was signiﬁ-
cantly shorter, while operating time was signiﬁcantly longer
(mean: 166 vs. 109 minutes) in the LAC arm. More costly OR
supplies were used in the LAC arm. Resource use was otherwise
similar between arms. The incremental costs were either mod-
estly higher in the LAC arm, $2,454 (95% CI $1,421–$3,485,
2007 US $) (C), or not statistically different, -$62 (95% CI
-$1,759–$1,608) (A) depending on the source of unit costs.
CONCLUSIONS: Economically, the choice between LAC and
OC consists of a tradeoff between higher operative costs and
shorter length of stay. The direction and magnitude of the net
effect depends on the cost inputs from a given institution, with
LAC relatively less expensive in institutions with higher ″hotel″
costs and less costly operative supplies. Future research should
focus on structured peri- and post-operative care to further opti-
mize the care and costs associated with LAC.
PCN46
COST-MINIMIZATION ANALYSIS OF CAPECITABINEVERSUS
UFT/LEUCOVORIN FORTHETREATMENT OF METASTATIC
COLORECTAL CANCER (MCRC) IN BRAZIL
Saggia MG1, Nasciben VD1, Santos EA1, Stefani S2
1Roche Brazil, Sao Paulo, SP, Brazil, 2UNIMED and Instituto do Câncer
Mãe de Deus, Porto Alegre, RS, Brazil
OBJECTIVES:Capecitabine (Xeloda) is an effective alternative to
treat metastatic colorectal cancer (mCRC) patients. This study
compares the costs of capacetabine and UFT/Leucovorin (UFT/
LV) in ﬁrst line therapy for patients with mCRC in Brazil.
METHODS: An analytic-decision model for projecting costs of
treating mCRC in Brazil was developed considering local guide-
lines, to compare costs of capecitabine (2500 mg/m2/day, d1-d14;
21 days-cycle) and UFT/LV (300 mg/m2/day of UFT, d1-d28; 35
days-cycle; 70mg of LV per day), under the payer perspective. The
time horizon of this analysis was 3.5-months, based on the
progression free survival (PFS) of UFT/LV showed in Douillard,
et al 2002 trial. In the absence of head-to-head trials, the same
efﬁcacy, in terms of PFS, was assumed for capecitabine and
UFT/LV. The safety proﬁles were obtained from Twelves, et al
2001 and Douillard, et al 2002. A panel of Brazilian specialists
was conducted to identify the local practices for treating adverse
events (AE). Costing was conducted based on public lists. For the
base case scenario a 1,7 m2 body surface patient was considered.
One-way sensitivity analysis was conducted to check the robust-
ness of the results. RESULTS: The total treatment cost of capecit-
abine is lower than UFT/LV: R$11,908 for capecitabine vs
R$19,417 for UFT/LV. Capecitabine has a lower acquisition cost
(R$3,205/month) than the UFT/LV scheme (R$4,457/month).
Capecitabine shows a better safety proﬁle thus costs for AE
management are lower thanUFT/LV (R$196 for CAP vs. R$1,089
forUFT/LV).CONCLUSIONS: Findings suggest capecitabine as a
cost-saving therapy under the payers’ perspective in Brazil. Total
savings could reach R$7,509 for a 3.5 month-period treatment.
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OBJECTIVES: An economic analysis was undertaken alongside
a trial evaluating chemotherapy with FOLFOX6: (5Fluouracil/
Leucovorin/Oxaliplatin) versus XELOX: (Capecitabine/
Oxaliplatin) as an adjuvant postoperative therapy for high risk
colorectal cancer patients. METHODS: In the absence of sur-
vival difference, a cost-minimisation analysis was undertaken.
Individual patient data (n = 169) were combined with 2008 unit
prices to estimate the cost of chemotherapy, administration,
medical consumables, drugs and laboratory testing. Patient
addresses were used to estimate travelling expenditure and
income data to evaluate productivity losses for those at produc-
tive ages. Raw data were bootstrapped 5000 times to correct for
distortions and to undertake statistical testing. RESULTS: From
a hospital perspective, the mean patient chemotherapy cost was
€8,866 with FOLFOX6 and €9723 with XELOX. Administra-
tion cost was €5,212 and €1,051, erythropoietin €2,787 and
€1,744 and total treatment cost €17,485 and €12,524 respec-
tively. Thus, XELOX reduced overall treatment cost by €4,961
(p  0.01). From a social insurance perspective, the mean che-
motherapy cost was €9,265 with FOLFOX6 and €10,160 with
XELOX. Administration cost was €3,113 and €185, erythropoi-
etin €2,789 and €1,713 and total treatment cost €15,797 and
€12,116 respectively. Thus, XELOX reduced total treatment cost
by €3680 (p  0.01). Mean patient travelling cost was €184 with
FOLFOX6 and 80€ with XELOX, a difference of €104 (p 
0.01). Mean productivity loss was €100 with FOLFOX6 and €31
with XELOX, a difference of €69 (p  0.01). CONCLUSIONS:
Apart from being more convenient for patients, oral chemo-
therapy with Capecitabine(Xeloda) reduces total treatment cost
for the NHS and Insurance Funds, as it reduces drastically the
cost of administration. It also reduces patient travelling time and
cost and productivity loss. Hence, it represents a cost saving and
advantageous approach to the management of operated colorec-
tal cancer patients.
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OBJECTIVES: A cost-minization analysis compared total costs
of XELOX (capecitabine + oxaliplatin) versus FOLFOX-6
(5-FU + folinic acid + oxaliplatin) in the ﬁrst line treatment for
patients with metastatic colorectal cancer (mCRC) in Brazil.
METHODS: An analytic-decision model for projecting costs of
treating mCRC in Brazil was developed considering local guide-
lines and the Brazilian payers’ perspective. According to the
phase III trial of Ducreux et al 2007, we assumed the same
efﬁcacy for XELOX and FOLFOX-6 in terms of progression
free-survival and overall survival. Only direct costs (drugs, IV
administration, physician fees, materials, etc.) were considered
for the chemotherapy and for treating adverse events. The time-
horizon of this analysis was 126 days according to the mean
number of Progression Free Survival found in the Ducreux clini-
cal trial (6 cycles of XELOX and 9 cycles of FOLFOX-6). For the
base case a patient with 1.7 m2 was considered. A Delphi panel
was conducted to identify local practices to manage the adverse
events of each scheme. Discount rate was not necessary because
of the short length of the analysis. RESULTS: Drug acquisition
costs for FOLFOX-6 were higher than XELOX (R$66,433 vs.
R$59,657). XELOX treatment generated a R$15,465 saving per
patient due to a 92% reduction in the number of IV administra-
tions. XELOX also presented a reduction of R$2,121.65 in costs
related to the management of adverse events. A one-way sensi-
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